Search

Marine ecosystems are under high demand for human use, giving concerns about how pressures from human activities may affect their structure, function, and status. In Europe, recent developments in mapping of marine habitats and human activities now enable a coherent spatial evaluation of potential combined effects of human activities. Results indicate that combined effects from multiple human pressures are spread to 96% of the European marine area, and more specifically that combined effects from physical disturbance are spread to 86% of the coastal area and 46% of the shelf area. We compare our approach with corresponding assessments at other spatial scales and validate our results with European-scale status assessments for coastal waters. Uncertainties and development points are identified. Still, the results suggest that Europe's seas are widely disturbed, indicating potential discrepancy between ambitions for Blue Growth and the objective of achieving good environmental status within the Marine Strategy Framework Directive.

Compound screening in biological assays and subsequent optimization of hits is indispensable for the development of new molecular research tools and drug candidates. To facilitate such discoveries, the European Research Infrastructure EU-OPENSCREEN was founded recently with the support of its member countries and the European Commission. Its distributed character harnesses complementary knowledge, expertise, and instrumentation in the discipline of chemical biology from 20 European partners, and its open working model ensures that academia and industry can readily access EU-OPENSCREEN's compound collection, equipment, and generated data. To demonstrate the power of this collaborative approach, this perspective article highlights recent projects from EU-OPENSCREEN partner institutions. These studies yielded (1) 2-aminoquinazolin-4(3 H)-ones as potential lead structures for new antimalarial drugs, (2) a novel lipodepsipeptide specifically inducing apoptosis in cells deficient for the pVHL tumor suppressor, (3) small-molecule-based ROCK inhibitors that induce definitive endoderm formation and can potentially be used for regenerative medicine, (4) potential pharmacological chaperones for inborn errors of metabolism and a familiar form of acute myeloid leukemia (AML), and (5) novel tankyrase inhibitors that entered a lead-to-candidate program. Collectively, these findings highlight the benefits of small-molecule screening, the plethora of assay designs, and the close connection between screening and medicinal chemistry within EU-OPENSCREEN.